Bob Nelsen exits board and president steps down at Unity as fallout from the anti-aging biotech's PhII miss continues
Unity Biotechnology is still reeling roughly four months after axing its lead program, as it saw significant change at the executive level Monday.
The company announced that ARCH Venture Partners’ Bob Nelsen, one of Unity’s co-founders back in 2011, has left the board. In addition, president and co-founder Ned David is stepping down at the end of the year, and another board member, David Lacey, is also leaving the biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.